A day before the Center for Disease Control and Prevention (CDC) committee is set to have a meeting about Johnson & Johnson COVID-19 The vaccine, the agency’s director, said he is “really hopeful” that the one-shot can be “used again soon.”

Speaking to Today, Dr. Rochelle Wallensky, whose agency together with the FDA recommended a halt in the rollout of the vaccine after six cases of a rare blood clot in more than 7 million vaccine recipients, said the agency needed to “decide quickly. “Will be. its use.

The day after the agencies recommended a stay, the AC Advisory Committee on Immunization Practices (ACIP) decided to extend it to allow more time to review the data and report potential reactions to patients.

Valensky had already said at the White House this week that the agency had only received “a handful” of possible reports, and that they were now working to verify whether those cases qualified as a case. .

The committee is tasked with deciding whether blood clots and low platelets should be listed as very rare side effects of the vaccine after unusual days of an EU panel. The European Medicine Agency (EMA) Safety Committee (PRAC) stated that “based on currently available evidence, specific risk factors have not been confirmed.”

How Long Does COVID-19 Vaccine Protection Last?

The PRAC review was based on six cases reported in the US, a seventh involving a clot outside the brain, and an eighth that involved a male during clinical trials, but not associated with the shot at the time Could have done. The rollout in Europe was halted by Johnson & Johnson following a recommendation by the US stagnation by the FDA and the CDC.

The European Union panel also noted that “perceived combinations of blood clots and low blood platelets are very rare, and the overall benefits of the COVID-19 vaccine Janssen reduce the risk of side effects of preventing COVID-19.” “

Previous women in COVID-19 vacancy are study members.

In the US, critics said the stagnation would contribute to the vaccination, adding that it would allow it to be delivered to communities at further risk of the virus as the vaccine is being deployed to these populations through mobile units and pop-up clinics. Easy to schedule storage requirements and a dosing facility vs. a second. However, proponents of stagnation said that continuing to use the jab in those hard-to-reach populations would also add barriers when trying to monitor for adverse reactions and make it difficult to provide emergency care.

Federal health officials have spent weeks praising the decision to stop the rollout, saying it is a sign that safety surveillance systems are working in the US.

Click here for complete coronary coverage

“The fact that following the EUA, we have continued to very carefully observe any possibility of adverse events, I believe is the other side of the coinage of hesitancy,” Dr. Anthony Fauci, the country’s leading infectious disease specialist, said. “It should be reinforced in those individuals how we take security so seriously, so in contrast to seeing it as a negative security issue, it can be seen as a positive issue where they know when We allow a vaccine to be available and it is to be put in the arms of the American people, we do it with great confidence as to its safety. So when I am asked a question about whether it made us hesitate Set back from perspective or not., I give the contrary. “